Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

 

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
A

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve ORR? Does Cilta-Cel Improve PFS? How to Improve Clinical Outcomes?

By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Adam D. Cohen
By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Adam D. Cohen
29 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Controversies and Update for Patient Care in Multiple Myeloma
17:23

UPenn Expert Analysis 40 y/o Patient With MM: How to Treat Systemica…

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace

33 views
10:17

UPenn Physicians Analyze a Challenging Case of MM: What Systemic The…

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace

201 views
15:36

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve …

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

A. Cohen

29 views
15:36

bsAb and IO for R/R MM in 2021: Are Teclistamab, Talquetamab, & Cevo…

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

A. Cohen

31 views
22:31

2021 Experimental Therapies for Relapsed Myeloma: Antibodies (Dara, …

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

D. Vogl

80 views